|[July 10, 2014]
Uppsala University Hospital and Elekta to Further Cancer Research in Sweden
STOCKHOLM --(Business Wire)--
Uppsala University Hospital (UUH) and Elekta (STO:EKTAB) today announced
that they have signed an agreement to jointly work at the forefront of
imaging in cancer care research.
With this research agreement, Uppsala University Hospital and Elekta
seek to contribute to the field of personalized care by using Magnetic
Resonance Imaging (MRI) and Positron Emission Tomography (PET).
In the future MRI potentially enables doctors to treat cancer with
radiation while seeing in real time where the tumor is and correct for
movement. This is limited with imaging used today.
Elekta, Philips (News - Alert) and some of the most renowned universities in the world
have started to do research into integrating MRI with linear
accelerators. This research is still at its early stages, but is
attracting interest from oncologists all over the world.
With this joint research agreement Uppsala intends to become the first
hospital in Sweden to receive a clinical system, once it has been
approved by the regulatory authorities (CE-mark). To prepare for this,
UUH has already started the building of new facilities, with bunkers
that are capable of receiving such treatment units of the future.
Kristina Nilsson, MD, PhD at Uppsala University Hospital commented: "We
envision that by using integrated MRI, in planning and implementation of
radiation therapy, future therapy will become more precise and better
adjusted to both the tumor and to nearby tissues, sensitive to
Elekta CEO Niklas Savander said: "We are convinced that combining
radiation therapy with MRI shall play a prominent role in the future of
cancer care. Elekta is proud that Uppsala University Hospital will
become a research partner in Sweden, helping us develop the clinical
approach to introducing such new techniques for the benefit of patients."
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was published at 08:00 CET on
July 10, 2014.
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning
systems for radiation therapy, radiosurgery and brachytherapy, as well
as workflow enhancing software systems across the spectrum of cancer
care. Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to
both health care providers and patients, Elekta aims to improve, prolong
and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,500 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on the Nordic Exchange under the ticker
STO:EKTAB. Website: www.elekta.com.
This information was brought to you by Cision http://news.cision.com
[ Back To TMCnet.com's Homepage ]